Form 4: Integra LifeSciences EVP Lea Daniels Knight Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Lea Daniels Knight, EVP & CFO of Integra LifeSciences, reports acquiring shares and stock options in the company on March 11, 2024.
Summary
- Lea Daniels Knight, an Executive Vice President and Chief Financial Officer at Integra LifeSciences Holdings Corp, filed a Form 4 on March 13, 2024.
- The form reports transactions that occurred on March 11, 2024.
- Ms. Knight acquired 11,822 shares of common stock at $0 and 8,283 shares of common stock at $0.
- Following these transactions, she directly owns 44,496 shares of common stock.
- She also acquired 27,308 non-qualified stock options with an exercise price of $36.22, vesting 25% annually over four years starting March 11, 2024, and expiring on March 11, 2032.
- Following the transaction, she owns 27,308 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing of insider transactions. The acquisitions themselves could be seen as slightly positive, but the filing itself is simply a procedural requirement.
Positives
- The acquisition of shares and stock options by a high-ranking executive could be interpreted as a positive signal about the executive's confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The vesting schedule of 25% per year is a fairly standard practice.
- Comparing the size of the stock option grant and share acquisitions to those of executives at comparable companies (e.g., Stryker, Medtronic, Boston Scientific) would provide further context.
Stakeholder Impact
- The reported transactions may influence investor sentiment regarding Integra LifeSciences.
- The acquisition of shares by an executive could be viewed positively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of earliest transaction: Acquisition of common stock and stock options. |
| 03/11/2024 | Grant date of stock options, with 25% vesting annually over four years. |
| 03/11/2032 | Expiration date of the non-qualified stock options. |
| 03/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.